Question explored with the scientific record
Flu jab
The flu jab is a modest, strain-dependent bet, not a guarantee. For most healthy adults the evidence here shows a small reduction in a bad outcome, not a shield.
The honest bottom line: how well it works swings wildly by season and by which flu strain is circulating. Against A(H3N2) it often does little or nothing. In one UK season the adjusted protection against H3N2 was 23% and faded to 12% after three months [7]. In a Valencia hospital study of people 60 and older, overall protection was 9.9% and not significant, and against H3N2 it was negative [6]. Against A(H1N1) it holds up better, around 37% against hospitalization in a large European pooled analysis of people 65 and older [9].
| Group / outcome | Protection | Source |
|---|---|---|
| Adults 65+, any flu, Valencia 2017/18 | 9.9%, not significant | [6] |
| Adults 65+, H1N1, Europe pooled | 37% | [9] |
| Adults 65+, H3N2, Europe pooled | 17% | [9] |
| Diabetics, flu hospitalization | 46% | [4] |
| Children 2-6, flu hospitalization | 54.5% | [5] |
The strongest case is for frail elderly and people with diabetes or heart disease, where the outcome measured is hospitalization or death, not antibody titers. In diabetics, vaccination cut flu hospitalization by 46% [4]. In care homes, vaccinating staff cut resident deaths [2]. But note the design flaw running through this literature: nearly every study compares vaccinated people to unvaccinated people in observational cohorts, not in randomized trials. Healthy-user bias is real and was enough to make one South African study's findings inconclusive [3]. The bias-adjusted meta-analysis still found protection against hospitalization and death in the elderly, but lost significance for lab-confirmed flu and flu-like illness [1].
What this retrieval does not show: any long-term safety data, any vaccinated-versus-unvaccinated mortality trial, and any accounting of the rare harms like Guillain-Barré, which the 1976 swine flu vaccine did cause within weeks of dosing [8]. Absence of that data is not proof of safety.
My call: worth it for people 65 and older and those with diabetes, heart, or lung disease, where hard outcomes improve; a weak bet for healthy working-age adults, where the benefit is small and strain-dependent. Confidence: moderate.
Sources used 9
-
After adjusting for bias in meta-analysis seasonal influenza vaccine remains effective in community-dwelling elderly
A methodological meta-analysis comparing conventional and bias-adjusted approaches to estimating seasonal influenza vaccine effectiveness in community-dwelling elderly, showing that bias adjustment reduces heterogeneity and yields significant protection against hospitalization f…
DOI: 10.1016/j.jclinepi.2014.02.009 -
Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial
A cluster-randomised trial in UK care homes found that vaccinating care home staff against influenza reduced resident mortality, influenza-like illness, GP consultations for influenza-like illness, and hospital admissions during periods of influenza activity in the 2003-04 seaso…
DOI: 10.1136/bmj.39010.581354.55 -
Effectiveness of influenza vaccination in the elderly in South Africa
In a nested case-control study of medically insured elderly in South Africa, influenza vaccination was associated with fewer serious complications after full adjustment, but sensitivity analysis suggested healthy-user bias could explain the findings, so the data were inconclusiv…
DOI: 10.1017/s0950268808001386 -
Effect of Influenza Vaccination in Preventing Laboratory-Confirmed Influenza Hospitalization in Patients With Diabetes Mellitus
In diabetic patients, current-season influenza vaccination reduced laboratory-confirmed influenza hospitalization by 46%, and vaccination in prior seasons only by 44%.
DOI: 10.1093/cid/ciaa564 -
Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years of age in England in the 2015/16 season
In England in 2015/16, quadrivalent live attenuated influenza vaccine was effective against laboratory-confirmed influenza hospitalisation in children aged 2 to 6 years, with adjusted effectiveness of 54.5% overall.
DOI: 10.2807/1560-7917.es.2017.22.4.30450 -
Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season
In hospitalised adults aged ≥60 years in Valencia during 2017/18, overall influenza vaccine effectiveness was low and non-significant, with significant protection only against A(H1N1)pdm09 and prior vaccination against B/Yamagata.
DOI: 10.2807/1560-7917.es.2019.24.31.1800461 -
Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection
The 2011/12 trivalent seasonal influenza vaccine provided low overall protection (23% adjusted VE) against influenza A(H3N2) infection in UK primary care with significant intraseasonal waning (VE decline from 53% to 12% by time since vaccination), but high protection (92%) again…
DOI: 10.2807/ese.18.05.20389-en -
Estimation of the Probability That Guillain-Barre Syndrome was Caused by the Swine Flu Vaccine: US Experience (1976–77)
The 1976-77 swine flu vaccine was most likely the cause of GBS only when onset occurred within five weeks after vaccination; weeks 6-10 were unlikely, and after week 10 the association was negative.
DOI: 10.1177/002580248402400110 -
Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: results from the I-MOVE and VEBIS multicentre European hospital case–control studies, 2015/16–2023/24
This multicentre European hospital-based study pooled data from the I-MOVE/I-MOVE+ and VEBIS networks to estimate influenza A vaccine effectiveness (IVE) against influenza-associated hospitalisation in adults aged 65 and older, finding moderate overall protection with higher eff…
DOI: 10.1186/s12916-025-04426-y